INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 3.23 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 414.92K shares, a 147.57% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 2.82M shares, a 25.83% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 288.40K shares, a 5.02% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 173.40K shares, a 38.99% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 2.87M shares, a 20.32% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 3.60M shares, a 18.17% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 3.05M shares, a 75.46% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 1.74M shares, a 284.88% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 414.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 3.23M shares 10-Q · filed 2026-08-06 | 3.52M shares derived: sum of 3 quarters · filed 2026-08-06 | 3.70M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 2.82M shares 10-Q · filed 2026-05-11 | 3.11M shares derived: sum of 2 quarters · filed 2026-05-11 | 3.28M shares derived: sum of 3 quarters · filed 2026-05-11 | 3.45M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 288.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 461.80K shares derived: sum of 2 quarters · filed 2026-02-26 | 629.40K shares derived: sum of 3 quarters · filed 2026-02-26 | 2.87M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 173.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 341.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.58M shares 10-Q · filed 2025-11-06 | 2.86M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 167.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.41M shares 10-Q · filed 2025-08-07 | 2.68M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.97M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.24M shares 10-Q · filed 2025-05-08 | 2.51M shares derived: sum of 2 quarters · filed 2025-05-08 | 2.80M shares derived: sum of 3 quarters · filed 2025-05-08 | 2.90M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 274.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 558.82K shares derived: sum of 2 quarters · filed 2025-02-27 | 662.37K shares derived: sum of 3 quarters · filed 2025-02-27 | 3.60M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 284.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 387.76K shares derived: sum of 2 quarters · filed 2024-11-07 | 3.33M shares 10-Q · filed 2024-11-07 | 3.60M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 103.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 3.04M shares 10-Q · filed 2024-08-08 | 3.32M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.32M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 2.94M shares 10-Q · filed 2024-05-09 | 3.21M shares derived: sum of 2 quarters · filed 2024-05-09 | 3.21M shares derived: sum of 3 quarters · filed 2024-05-09 | 3.43M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 273.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 273.27K shares derived: sum of 2 quarters · filed 2024-02-22 | 491.78K shares derived: sum of 3 quarters · filed 2024-02-22 | 3.05M shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 0.00 shares 10-Q · filed 2023-11-09 | 218.51K shares derived: sum of 2 quarters · filed 2023-11-09 | 2.77M shares 10-Q · filed 2023-11-09 | 2.79M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 218.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.70M shares 10-Q · filed 2023-08-03 | 2.79M shares derived: sum of 3 quarters · filed 2023-08-03 | 2.79M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-03-31 | 2.48M shares 10-Q · filed 2023-05-04 | 2.57M shares derived: sum of 2 quarters · filed 2023-05-04 | 2.57M shares derived: sum of 3 quarters · filed 2023-11-09 | 2.90M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | 88.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 88.18K shares derived: sum of 2 quarters · filed 2023-11-09 | 417.90K shares derived: sum of 3 quarters · filed 2023-11-09 | 1.74M shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 0.00 shares 10-Q · filed 2023-11-09 | 329.72K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.65M shares 10-Q · filed 2022-11-03 | 1.42M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 329.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 1.33M shares 10-Q · filed 2022-08-04 | 1.42M shares derived: sum of 3 quarters · filed 2022-08-04 | 1.43M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 997.70K shares 10-Q · filed 2022-05-05 | 1.09M shares derived: sum of 2 quarters · filed 2022-05-05 | 1.10M shares derived: sum of 3 quarters · filed 2022-05-05 | 1.19M shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 97.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 98.20K shares derived: sum of 2 quarters · filed 2022-02-24 | 191.43K shares derived: sum of 3 quarters · filed 2022-02-24 | 451.27K shares 10-K · filed 2022-02-24 |
| 2021-09-30 | 1.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 94.23K shares derived: sum of 2 quarters · filed 2021-11-04 | 354.07K shares 10-Q · filed 2021-11-04 | 433.39K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 93.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 353.07K shares 10-Q · filed 2021-08-05 | 432.39K shares derived: sum of 3 quarters · filed 2021-08-05 | 432.39K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 259.84K shares 10-Q · filed 2021-05-06 | 339.15K shares derived: sum of 2 quarters · filed 2021-05-06 | 339.15K shares derived: sum of 3 quarters · filed 2021-05-06 | 339.15K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 79.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 79.32K shares derived: sum of 2 quarters · filed 2021-02-26 | 79.32K shares derived: sum of 3 quarters · filed 2021-02-26 | 260.34K shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-05 | 181.02K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 181.02K shares 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | 181.02K shares 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2019-02-27 | 14.38K shares derived: sum of 3 quarters · filed 2019-02-27 | 86.25K shares 10-K · filed 2019-02-27 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | 14.38K shares derived: sum of 2 quarters · filed 2018-10-31 | 86.25K shares 10-Q · filed 2018-10-31 | |
| 2018-06-30 | 14.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | 86.25K shares 10-Q · filed 2018-08-01 | ||
| 2018-03-31 | 71.88K shares 10-Q · filed 2018-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |